|Image courtesy: WHO/H.M. Dias.|
Post by Tamilarasu Kadhiravan.
Kadhir is an academic physician based at the Jawaharlal Institute of Medical Education and Research (JIPMER) at Puducherry, in South India; interested in tropical infectious diseases research, particularly tuberculosis. Here, he blogs about the Cochrane review he recently co-authored: Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.